SRC-Family Kinase and Macrophage Activation Inhibitors for Lupus Nephritis Identified by Single-Cell RNA Sequencing of Peripheral Blood Mononuclear Cells and Computational Drug Repurposing

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Lupus Nephritis (LN) is the most severe manifestation of Systemic Lupus Erythematosus, affecting approximately 50% of SLE patients with limited effective therapies. We applied a computational drug repurposing pipeline to single-cell RNA sequencing data from SLE/LN patient peripheral blood mononuclear cells (GSE135779; Arazi et al., Nature Immunology 2019; 84,000 cells; 12 clusters). Differential expression analysis of macrophage/monocyte clusters identified 6,956 LN-dysregulated genes, from which 125 ChEMBL-tractable targets were extracted spanning SRC-family kinases (HCK, LYN, FGR), macrophage activation markers (CD14, PLEK, RAC1), metabolic regulators (NAMPT, TKT), and lysosomal cathepsins (CTSB, CTSD, CTSS). Systematic screening of 12,459 unique compounds (pChEMBL >= 7.5) with USPTO prior art verification identified all 12,459 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (8 targets, score 88.5), DASATINIB (CHEMBL5416410, FDA-approved BCR-ABL/SRC inhibitor, 5 targets, score 59.5), PONATINIB (CHEMBL1171837, 4 targets, score 50.0), and CHEMBL3342183 (triple lysosomal cathepsin inhibitor CTSB/CTSD/CTSS, highest pChEMBL 10.96 in top 10, score 41.0). The SRC-family kinase triad HCK/LYN/FGR dominates the top 10 — appearing in 7 of 10 compounds across multiple chemically distinct scaffolds, providing strong biological validation of this axis. NAMPT (NAD+ biosynthesis rate-limiting enzyme) identified as a novel LN therapeutic target via CHEMBL5653589. DASATINIB achieves NOVEL_ALL USPTO status for lupus nephritis, providing a near-term repurposing opportunity with an established human safety profile. These findings are the basis of a filed USPTO provisional patent application (Ritschel Research, Micro-Entity, March 2026). Provisional patent specification: [add spec DOI after upload]. Pipeline code: https://github.com/glenritschel/lupus-nephritis-scrna

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Computational Drug Discovery Methods Natural Compounds in Disease Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
27 March 2026
Language
EN
Document type
Preprint